FDA Clearance Tracker · P040024-S099
Restylane Lyft with Lidocaine
Last checked: Nov 20, 2026Latest source record: May 18, 2018 (this decision)Source: openFDAMethods & limitations
Decided
May 18, 2018
Approved
Time to decision
262 days
Received Aug 29, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the Restylane Lyft with Lidocaine for expanding the indications to include injection into the subcutaneous plane in the dorsal hand to correct volume deficit in patients over the age of 21
Source documents
Other decisions for Q-Med AB
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Restylane® ContourPMA supplement
P140029-S054 · Decided Mar 20, 2026 · 239 days after receipt · Panel Track
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.